Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Presence of draining tunnels denotes a distinct hidradenitis suppurativa phenotype","authors":"Thrasyvoulos Tzellos, Christos C. Zouboulis","doi":"10.1111/jdv.20792","DOIUrl":"https://doi.org/10.1111/jdv.20792","url":null,"abstract":"<p>The cross-sectional survey with retrospective data collection by Ingram et al. published in this issue targets the characterization of the clinical profile of patients with moderate-to-severe hidradenitis suppurativa (HS) with and without draining tunnels.<span><sup>1</sup></span> It came to the expected result that patients with draining tunnels had more inflammatory nodules, abscesses and scarring. Furthermore, the presence of draining tunnels was associated with significantly more inflammation/redness, drainage from lesions, pain on sitting, low mood/depression, sleep disturbance and fatigue. Physicians agreed that patients with draining tunnels experienced a negative impact of disease on their daily life, mental health, and sexual function compared to those without.</p><p>This evidence further enhances the notion that the presence of draining tunnels denotes a distinct HS phenotype with more severe disease, which depicts disease progression and exhibits a poorer response to many current HS treatments. Dermal tunnels are structures unique to HS and are associated with a more severe disease, cause significant pain and morbidity via chronic, malodorous discharge and have a detrimental impact on quality of life.<span><sup>2</sup></span> It has been suggested that the presence of tunnels is associated with a more aggressive course of Hurley stage 3 disease.<span><sup>2</sup></span></p><p>Furthermore, individual patient data analysis from the PIONEERs phase 3 adalimumab trials employing time-to-event analyses was performed to estimate time to achieve HiSCR and time to loss of HiSCR, whereas the presence of dermal tunnels significantly negatively influenced the odds of achieving HiSCR and the time to achieve HiSCR with adalimumab.<span><sup>3</sup></span> It was proven that integrating draining tunnel status [using the International Hidradenitis Severity Score System (IHS4)] reduced placebo response rates in both PIONEER studies regardless of if a binary or continuous variable was used. Effective treatments against draining tunnels are still an unmet need in the HS treatment.</p><p>HS samples with tunnels have a distinct molecular profile compared to HS samples without tunnels.<span><sup>2</sup></span> HS tunnels were at least in part dependent on IL-17 signalling. It is suggested that the response of the subcutaneous nodules to TNFα blockade and not the tunnels suggests that the cellular migration to and across tunnel epithelium is more dependent on IL-17 signalling rather than TNF-α signalling. Taken together, these data demonstrate a novel avenue for the development of therapeutics for this devastating disease and treatment with the newly developed and approved drugs bimekizumab and secukinumab, which target different subunits of IL-17 and seem promising in decreasing dermal tunnel drainage and in the resolution of sinus tracts.</p><p>All this evidence clearly suggests that the presence of draining tunnels should be considered a potential mark","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 8","pages":"1372-1373"},"PeriodicalIF":8.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20792","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate in mycosis fungoides revisited","authors":"Reinhard Dummer, Ariane Suter","doi":"10.1111/jdv.20789","DOIUrl":"https://doi.org/10.1111/jdv.20789","url":null,"abstract":"<p>Primary cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by the accumulation of skin-homing lymphocytes, leading to macular or, in later stages, nodular skin lesions. Mycosis fungoides (MF) is the most common entity among CTCL. Diagnosis is based on clinical features and is supported by histological and molecular biological findings.<span><sup>1</sup></span> The treatment of MF, apart from allogenic stem cell transplantation, is palliative; therefore, maintaining quality of life is the primary focus. Topical therapies are the most frequently used first-line treatments, including corticosteroids, chlormethine or UV radiation (nbUVB or PUVA).<span><sup>1, 2</sup></span> If these measures are insufficient, immunomodulatory medications are often introduced combination with UV therapy. Candidate medications are methotrexate (MTX), Interferon alpha (IFN-<i>α</i>) and bexarotene.<span><sup>2</sup></span> Each of them can be combined well with UV treatment. Unfortunately, access to INF-<i>α</i> and bexarotene is currently limited due to logistical and financial reasons. Therefore, MTX often is the only immunomodulatory medication readily available.</p><p>For oncologic indications, MTX is typically administered at high doses and functions as an anti-folate antimetabolite. In contrast, low-dose MTX is well established in the treatment of various inflammatory conditions, including psoriasis and rheumatoid arthritis.<span><sup>2</sup></span> Under these circumstances, the mechanism of action might differ: MTX activates the enzyme AICAR, which inhibits AMP deaminase, leading to an accumulation of adenosine.<span><sup>3</sup></span> The resulting adenosine accumulation in lymphocytes results in reduced proliferation and activity of T cells. In CTCL, MTX is administered at low doses, probably due to its direct impact on T-cell proliferation. There are only a few reports on the current tolerability and efficacy of this medication in this context.<span><sup>2</sup></span></p><p>Nikolaou et al. report a retrospective multicentral series of 211 MF patients in Greece. MTX was administered either as monotherapy (112 patients) or combination therapy with various other treatments including phototherapy (<i>n</i> = 31), INF-<i>α</i> (<i>n</i> = 29; 25 received INF-<i>α</i> 2b,4 received pegylated interferon) and retinoids (<i>n</i> = 12; bexarotene and/or acitretin). MTX was given once weekly with a median oral dose of 15 mg/week, reflecting a low-dose approach.<span><sup>4</sup></span> Unfortunately the patient population is very heterogenous: 124 patients had late-stage disease (IIB-IVB). Moreover, there was no information provided on CD30 expression level within the cohort. First line treatment in patients with early staged MF showed a progression free survival (PFS) of more than a year<span><sup>4</sup></span> which is notably longer than what has been reported in prospective trials such as ALCANZA.</p><p>In this ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 8","pages":"1374-1375"},"PeriodicalIF":8.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20789","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SmartProg-MEL-integrating dermatopathology and explainable artificial intelligence (AI) to improve prognostic accuracy and risk stratification in cutaneous melanoma","authors":"Franco Rongioletti, Stefania Guida","doi":"10.1111/jdv.20776","DOIUrl":"https://doi.org/10.1111/jdv.20776","url":null,"abstract":"<p>In the era of precision oncology, artificial intelligence (AI) is increasingly recognized for its potential to transform histopathological workflows and prognostic stratification. The study by Bossard et al.<span><sup>1</sup></span> introduces <i>SmartProg-MEL</i>, a deep learning–based model developed to predict 5-year overall survival (OS) in patients with primary cutaneous melanoma (stages I–III), using only routine haematoxylin–eosin (HE) or HE-saffron–stained whole slide images (WSIs). By offering an explainable, image-based prognostic tool, SmartProg-MEL aims to complement or surpass traditional clinicopathological risk assessments.</p><p>A major strength of this study lies in its robust validation across multiple independent cohorts. The model was trained on a discovery dataset of 342 patients (IHP-MEL-1) and externally validated on two independent sets: IHP-MEL-2 (<i>n</i> = 161) and TCGA (<i>n</i> = 63). It consistently achieved concordance indices of 0.72, 0.71 and 0.69, respectively, with sensitivity ranging from 71% to 100%. These metrics outperform earlier AI prognostic tools,<span><sup>2-4</sup></span> which were often limited by small datasets and lack of external validation. Notably, SmartProg-MEL maintained high performance across varying staining protocols and scanner types, supported by robust stain normalization and augmentation techniques—critical for clinical translation.</p><p>Clinically, the model's utility is underscored by its ability to refine prognostic classification beyond the current AJCC TNM staging system.<span><sup>5</sup></span> For instance, it identified high-risk patients within stage I melanomas—traditionally considered low risk—and reclassified a significant portion of stage IIB/IIC cases as low risk. Such refined stratification could support tailored decisions around surveillance intensity and adjuvant immunotherapy, potentially sparing low-risk individuals from overtreatment while ensuring timely intervention for those at greater risk.</p><p>Equally notable is the emphasis on interpretability. Using attention-based heatmaps and UMAP-based feature clustering, the model highlights morphologic correlates of risk. Features such as nuclear pleomorphism, cellular atypia, architectural disorganization and peritumoral immune infiltrates align with established histopathological prognostic factors. This transparency enhances clinician trust and positions SmartProg-MEL not merely as a ‘black box’ tool, but as an interpretable digital biomarker.</p><p>However, several limitations warrant discussion. The retrospective design introduces inherent selection biases, and treatment-related variables during follow-up were not incorporated into the survival models. This is particularly relevant given the growing impact of systemic therapies on melanoma outcomes. Furthermore, although SmartProg-MEL performed well across cohorts, a slight dip in performance in the TCGA set may reflect technical and biological heterogeneity. ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 8","pages":"1380-1381"},"PeriodicalIF":8.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rook's textbook of dermatology, 10th ed. By CEM Griffiths, JNWN Barker, TO Bleiker, RJG Chalmers, D Creamer (Eds.), Oxford: Wiley-Blackwell. 2024","authors":"Georgios Nikolakis","doi":"10.1111/jdv.20862","DOIUrl":"https://doi.org/10.1111/jdv.20862","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 10","pages":"1846-1847"},"PeriodicalIF":8.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study’","authors":"","doi":"10.1111/jdv.20829","DOIUrl":"10.1111/jdv.20829","url":null,"abstract":"<p>Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Tsianakas A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. <i>J Eur Acad Dermatol Venereol</i>. 2025; 39: 1152–1162. https://doi.org/10.1111/jdv.20526.</p><p>We have noted errors in the tables under Figures 1 and 3. The corrected figures are presented below.</p><p>We apologize for this error.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 9","pages":"1687-1689"},"PeriodicalIF":8.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20829","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing, age and immune profiling refine strategy in lichenoid chronic graft-versus-host disease","authors":"Shiuan-Chih Chen,&nbsp;Tsai Ling Ting","doi":"10.1111/jdv.20823","DOIUrl":"10.1111/jdv.20823","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 10","pages":"e934-e935"},"PeriodicalIF":8.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups","authors":"Sonja Ständer,&nbsp;Emma Guttman-Yassky,&nbsp;Gil Yosipovitch,&nbsp;Henning Wiegmann,&nbsp;Dieter Metze,&nbsp;Madeline Kim,&nbsp;Ester Del Duca,&nbsp;Kent Bondensgaard,&nbsp;John F. Paolini,&nbsp;The LOTUS-PN Investigators Group","doi":"10.1111/jdv.20812","DOIUrl":"10.1111/jdv.20812","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Prurigo nodularis (PN) is a severe, intensely pruritic subtype of chronic prurigo for which the molecular basis and interplay between pathophysiologic mechanisms and clinical manifestations are poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>LOTUS-PN was a longitudinal observational study that included 54 participants from 11 centers and was designed to improve disease understanding. Protein expression, histology and RNA analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Histologically, all patients had typical PN characteristics. Immunohistochemically, and on the mRNA level, expression in lesional versus non-lesional samples for IL-31 (<i>p</i> &lt; 0.01) was significantly higher. In addition, immunohistochemistry showed higher expression of IL-31RA (<i>p</i> &lt; 0.05), OSM (<i>p</i> &lt; 0.05) and OSMRß (<i>p</i> &lt; 0.01). PN lesional skin showed higher expression of Th2 and Th17/Th22 pathway markers. A correlation analysis of gene expression highlighted two groups of intra-marker correlations dividing the Th2 markers, the first containing barrier and regulatory genes and the other containing markers of general inflammation that correlated negatively and positively with Th17/Th22 genes, respectively. Correlations between gene expression and NRS scores were weak and involved genes associated with general inflammation (<i>MMP12</i>) and Th2 (<i>IL10</i>, <i>CCL18</i>, <i>IL4R</i>).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study confirms the role of Th2 signature in PN and the dominant role of IL31. Correlation analysis of gene expression showed differing relationships between subsets of the Th2 axis with Th1 and Th17/Th22 markers, highlighting the potential of different components of the Th2 pathway to interact with and modulate other immune axes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 10","pages":"1750-1759"},"PeriodicalIF":8.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20812","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to make dermatology conferences more sustainable?","authors":"Branka Marinovic","doi":"10.1111/jdv.20755","DOIUrl":"https://doi.org/10.1111/jdv.20755","url":null,"abstract":"<p>I read with great interest the Letter to the editor, submitted to the JEADV by Lim and co-authors, titled Exploring the Environmental Sustainability of Dermatology Conferences.<span>¹</span> They compared findings from exhibitions at two congresses of the European Academy of Dermatology and Venereology (EADV) and one Annual Scientific Meeting of the British Association of Dermatology (BAD). The authors assessed various aspects of samples collected and estimated the average carbon footprint associated with those samples, but they also gave some ideas about how we could collectively make improvements.</p><p>In recent years, sustainability has emerged as an important topic within the EADV, especially under the presidency of the immediate past president, Professor Martin Roecken. However, initiatives focused on sustainability at EADV Congresses began at an operational level prior to this period with the discontinuation of congress bag production and the shift to digital programme books, adjustments that elicited mixed responses from attendees. As stated in the Letter by Lim et al., the EADV Congress in Amsterdam offered reusable cups, made food donations and promoted public transport, as well as the use of bicycles. Furthermore, the formation of the EADV Climate Working Group 2 years ago has been instrumental in helping to address environmental concerns. The main goal is to promote awareness about the problem, highlight the effect of climate change on dermatological disease and show how dermatologists can help.</p><p>From the COVID-19 pandemic, we learned valuable lessons, notably the potential for conducting numerous activities online. In-person meetings remain essential for exchanging knowledge, experiences and ideas, as well as being part of human nature to meet and interact with colleagues. This necessity underscores the imperative to enhance the sustainability of conferences, which have a significant carbon footprint. Such events are usually attended by many attendees who often travel long distances by air, but also stay in hotels, generating substantial waste through single-use plastics, printed materials and food services.</p><p>Big dermatological societies, including EADV, are working on how to adopt sustainable practices further. Some strategies include the possibility of a hybrid meeting (if we do not think about the footprint produced by IT), choosing venues that prioritize sustainability, providing local sources of food and the provision of reusable water bottles. Some other options are to discuss sustainability with exhibitors to further align the exhibition with sustainability objectives. Lim et al. stated that an improvement is already visible, but there is still more intensive work to be done on the topic. Sustainability should not be perceived as a constraint but rather as an opportunity for innovation. Just as dermatology continuously adapts to emerging technologies and skincare research, it can also pioneer environmen","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 7","pages":"1222-1223"},"PeriodicalIF":8.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20755","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib: Long-term safety and efficacy reaffirm its place in the psoriasis treatment landscape","authors":"Ion Birkenmaier,&nbsp;Sezgi Sarikaya Solak,&nbsp;Julia-Tatjana Maul","doi":"10.1111/jdv.20751","DOIUrl":"https://doi.org/10.1111/jdv.20751","url":null,"abstract":"<p>Deucravacitinib is an oral, highly selective TYK2 inhibitor approved for the treatment of moderate to severe plaque psoriasis.<span>^{1, 2}</span> A key aspect that differentiates this allosteric inhibitor from other oral immunomodulators is its selective binding to the regulatory domain of TYK2, avoiding inhibition of JAK1, JAK2 and JAK3. This selectivity enables targeted modulation of IL-12, IL-23 and type I interferon pathways, resulting in a distinct and potentially more favorable safety profile.<span>^{1, 2}</span></p><p>Armstrong et al.<span>¹</span> present 4-year results from the POETYK PSO-1, PSO-2 and their long-term extension trials, offering key insights into the durability of deucravacitinib's efficacy and safety. Given the chronic, immune-mediated nature of psoriasis, such findings are particularly relevant as they highlight the need for durable systemic treatment options.</p><p>The data are encouraging<span>¹</span> – patients treated continuously with deucravacitinib maintained stable PASI 75 (72.0% at year one vs. 71.7% at year four) and PASI 90 response rates (45.6% at year one vs. 47.5% at year four) over 4 years. Nearly half of patients achieved DLQI 0/1, indicating minimal or no impact on their quality of life. Importantly, the safety outcomes remained stable throughout the 4393 patient-years of exposure, with low and consistent rates of serious infections, malignancies, major cardiovascular events and venous thromboembolism. Notably, no new safety concerns emerged and discontinuations due to adverse events decreased over time.</p><p>Certain limitations, however, must be considered. As an open-label extension, the study inherently includes a responder bias, as participants who did not benefit or tolerate treatment in the initial phase likely discontinued. Moreover, the apremilast arm was discontinued after year 1, preventing direct long-term comparisons of efficacy and safety against other therapies, including newer biologics and oral agents.</p><p>Despite these limitations, Armstrong et al. provide robust evidence supporting deucravacitinib's role as a reliable long-term oral therapy for moderate to severe psoriasis. Importantly, in contrast to other JAK inhibitors, deucravacitinib has not been subject to a black box warning by the FDA. This is significant, particularly considering FDA concerns surrounding cardiovascular and malignancy risks with JAK1/2/3 inhibitors. The presented 4-year data thereby further reinforce the benefits of TYK2 selectivity.</p><p>The February 2025 update of the EuroGuiDerm guideline nevertheless recommends monitoring full blood count, liver enzymes, creatine phosphokinase and lipid profile where clinically indicated, every 3–6 months during treatment and advises treatment interruption if myopathy or liver injury is suspected.<span>³</span> Reassuringly, the 4-year data did not show clinically meaningful changes from baseline in terms of laborator","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 7","pages":"1220-1221"},"PeriodicalIF":8.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pioneers in Dermatology and Venereology: An interview with Professor Michael Landthaler","authors":"Michael Landthaler","doi":"10.1111/jdv.20716","DOIUrl":"https://doi.org/10.1111/jdv.20716","url":null,"abstract":"<p>\u0000 \u0000 </p><p>Year of birth: 1948</p><p>Professor Otto Braun-Falco's dermatology lecture was among the most inspiring experiences I had in Munich. Coincidentally, my final state examination concluded with dermatology, and our group performed exceptionally well that the senior physician examiner offered each of us a position. I seized the opportunity to take up a position at the prestigious Munich clinic, and I quickly realized that dermatology was the medical specialty where I truly belonged.</p><p>My most influential teacher was, of course, Professor Otto Braun-Falco who led the Munich clinic. Other key mentors in my academic development included the senior physicians Professor Plewig, Professor H.H. Wolff, Professor Dorn, and Dr. Konz.</p><p>Naturally, I learned the most from Professor Otto Braun-Falco, who embodied the academic triad of patient care, teaching, and research, setting a daily example for his team.</p><p>When assuming a chair, one receives plenty of valuable advice on patient care, teamwork, teaching and more. I found meaningful guidance from the Rule of Saint Benedict of Nursia (480-547 CE), whose principles resonate with the responsibility of managing a clinic and caring for patients. One example reads “<i>He should know that whoever undertakes the government of souls must prepare himself to account for them.</i>” Another passage says: “<i>It is not the healthy who need a physician, but the sick […] Care for the sick must rank before and above all else […] Let the sick, on their part, bear in mind that they are served out of honour for God, and let them not by their excessive demands distress anyone who serves them. Still, sick monks must be patiently borne with, because serving them leads to a greater reward.</i>” Finally, regarding the role of an abbot (comparable to the head of the clinic), I would like to quote: “<i>He should always remember what he is and what he is called, and should know that to whom more is committed, from him more is required</i>.”</p><p>Yes, I served as Dean of the Medical Faculty at the University of Regensburg from 1994 to 2000, followed by a term as Vice Rector of the University from 2000 to 2002. I was also a Member of the Presidium of the German Dermatological Society from 2007 to 2013 and Deputy Medical Director of the University Hospital Regensburg from 2001 to 2011.</p><p>I had the opportunity to contribute to the development of dermatology in Regensburg, helping to establish a dermatology clinic, a university clinic and a medical faculty, which are now firmly integrated into the university structure. Furthermore, I am glad that three senior physicians from the clinic in Regensburg now lead dermatology clinics across Germany: Professor Stolz in Munich, Professor Vogt in Homburg/Saar and Professor Szeimies in Recklinghausen. I am particularly proud of the appreciation the junior doctors expressed upon my retirement with these words: “<i>In particular, we would like to thank","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 7","pages":"1224-1227"},"PeriodicalIF":8.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20716","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144472971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}